Efficacy and safety of trastuzumab combined with docetaxel in treatment of human epidermal growth factor receptor 2-positive advanced breast cancer
10.3760/cma.j.cn115355-20240723-00364
- VernacularTitle:曲妥珠单抗联合多西他赛治疗人表皮生长因子受体2阳性晚期乳腺癌的效果及安全性
- Author:
Xianling WANG
1
;
Qian JIANG
1
Author Information
1. 山西省肿瘤医院 中国医学科学院肿瘤医院山西医院 山西医科大学附属肿瘤医院放疗科，太原 030013
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Human epidermal growth factor receptor 2;
Treatment outcome;
Trastuzumab;
Docetaxel
- From:
Cancer Research and Clinic
2024;36(12):942-946
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of trastuzumab combined with docetaxel in the treatment of advanced breast cancer patients with positive human epidermal growth factor receptor 2 (HER2).Methods:A retrospective case series study was conducted. Sixty-six HER2-positive advanced breast cancer patients who were admitted to Shanxi Province Cancer Hospital from January 2017 to October 2022 were selected. The 35 patients who were treated with docetaxel from January 2017 to December 2019 were included in the control group, and the 31 patients who were treated with trastuzumab combined with docetaxel from January 2020 to October 2022 were included in the observation group. The clinical efficacy after 4 cycles of treatment, immune function and tumor markers before and after 4 cycles of treatment, adverse reactions during follow-up, and recurrence and survival status after 1 year of follow-up were compared between the two groups.Results:There was no statistically significant difference in general information of patients such as age, gender, pathological type, differentiation degree, TNM staging, and status of distant metastasis between the two groups (all P > 0.05). After 4 cycles of treatment, the overall response rate of the observation group was higher than that of the control group [70.97% (22/31) vs. 45.71% (16/35)], and the difference was statistically significant ( χ2 = 4.29, P = 0.038). Compared with before treatment, after 4 cycles of treatment, the levels of CD3 +, CD4 + and CD4 +/CD8 + in peripheral blood of both groups were higher, and the levels in the observation group were higher than those in the control group (all P < 0.05); the level of peripheral blood CD8 + in both groups were lower after 4 cycles of treatment, and the level in the observation group was lower than that in the control group (all P < 0.05). Compared with before treatment, after 4 cycles of treatment, the levels of serum carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 153, and tissue peptide specific antigen in both groups were lower, and the levels in the observation group were lower than those in the control group (all P < 0.05). During the follow-up period, there was no statistically significant difference in the incidence of adverse reactions between the two groups (all P > 0.05). After 1 year of follow-up, the recurrence rate in the observation group was lower than that in the control group [9.68% (3/31) vs. 34.29% (12/35)], and the difference was statistically significant ( χ2 = 5.67, P = 0.017); the survival rate of the observation group was higher than that of the control group [67.74% (21/31) vs. 40.00% (14/35)], and the difference was statistically significant ( χ2 = 5.08, P = 0.024). Conclusions:Trastuzumab combined with docetaxel chemotherapy could effectively reduce the levels of tumor markers, improve the immune function of patients, reduce the recurrence, and improve the survival rate of HER2-positive advanced breast cancer patients, and the regimen is safe.
